Overactive bladder

Axonics® Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, October 31, 2022

Net revenue was $70.4 million in third quarter 2022, an increase of 50% compared to $46.9 million in the prior year period.

Key Points: 
  • Net revenue was $70.4 million in third quarter 2022, an increase of 50% compared to $46.9 million in the prior year period.
  • Gross margin was 72.8% in third quarter 2022 compared to 66.5% in the prior year period.
  • Net loss was $16.3 million in third quarter 2022 compared to net loss of $17.3 million in the prior year period.
  • Axonics will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results and recent business developments.

BlueWind Medical Announces New Executive Appointments

Retrieved on: 
Tuesday, November 1, 2022

PARK CITY, Utah and HERZLIYA, Israel, Nov. 1, 2022 /PRNewswire/ --BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder (OAB), announced three executive appointments to leadership positions within the company.

Key Points: 
  • PARK CITY, Utah and HERZLIYA, Israel, Nov. 1, 2022 /PRNewswire/ --BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder (OAB), announced three executive appointments to leadership positions within the company.
  • "This group of talented professionals bring mature and multinational company experience," said Dan Lemaitre, Chairman and CEO of BlueWind Medical.
  • Seamus O'Connor brings 23 years of experience in the medical device industry across quality assurance and regulatory affairs, working with various medical device technologies.
  • Prior to BlueWind Medical, Seamus held positions of increasing responsibility at MEDNOVA, TE Connectivity, Boston Scientific and Natus Medical.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

NEUSPERA MEDICAL® ANNOUNCES FIRST SUCCESSFUL IMPLANT OF THE NUVELLA™ SYSTEM IN THE SECOND PHASE OF ITS SANS-UUI IDE CLINICAL TRIAL

Retrieved on: 
Monday, October 10, 2022

SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The procedure was performed by Dr. Jodi Michaels of Minnesota Urology, St. Paul, MN. The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms.

Key Points: 
  • The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms.
  • "This system has the ability to treat UUI symptoms with the smallest available implant, significantly improving the patient experience."
  • The Nuvella system delivers neuromodulation therapy through a wireless, less invasive, and more versatile platform than commercially available technology.
  • Kicking off enrollment builds on the strong momentum from our feasibility experience," commented Steffen Hovard, CEO of Neuspera Medical.

Axonics® to Report Third Quarter 2022 Financial Results on October 31

Retrieved on: 
Monday, October 10, 2022

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31.
  • Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.
  • Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: Axonics 3Q22 registration .
  • 1 on the 2021 Deloitte Technology Fast 500 and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Global Nephrology and Urology Devices Market Report (2022 to 2030) - Rising Demand For Antimicrobial Catheters is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022

The "Nephrology and Urology Devices Market Size, Share & Trends Analysis Report by Product (Ureteral Catheters, PCN Catheters, Urology Guidewires), by Application, by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nephrology and Urology Devices Market Size, Share & Trends Analysis Report by Product (Ureteral Catheters, PCN Catheters, Urology Guidewires), by Application, by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global nephrology and urology devices market size is anticipated to reach USD 9.44 billion by 2030, according to this report., expanding at a CAGR of 6.8% from 2022 to 2030.
  • This is anticipated to increase the demand for nephrology and urology devices during the forecast period.
  • These factors have led to an increase in the sale of nephrology and urology devices in the market.

UnitedHealthcare’s 2023 Medicare Plans Add New Benefits, Simplicity for Consumers

Retrieved on: 
Saturday, October 1, 2022

Medicare National Network: The largest national Medicare Advantage networkv will be available across even more plans in 2023, reaching nearly 96% of people in UnitedHealthcares coverage area and more than 3.1 million current enrollees.

Key Points: 
  • Medicare National Network: The largest national Medicare Advantage networkv will be available across even more plans in 2023, reaching nearly 96% of people in UnitedHealthcares coverage area and more than 3.1 million current enrollees.
  • Plans are insured or covered by a Medicare Advantage organization with a Medicare contract and/or a Medicare-approved Part D sponsor.
  • For Dual Special Needs Plans: A Medicare Advantage organization with a Medicare contract and a contract with the State Medicaid Program.
  • iiiRefers to UnitedHealthcares standard Medicare Advantage plans (i.e., non-special needs plans).

BlueWind Medical Appoints Dr. Liz Kwo to Board of Directors

Retrieved on: 
Tuesday, September 27, 2022

PARK CITY, Utahand HERZLIYA,Israel, Sept.27, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., a medical device company working to transform neuromodulation therapy for overactive bladder (OAB), announced today that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company's Board of Directors.

Key Points: 
  • PARK CITY, Utahand HERZLIYA,Israel, Sept.27, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., a medical device company working to transform neuromodulation therapy for overactive bladder (OAB), announced today that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company's Board of Directors.
  • "I am pleased to join BlueWind Medical at this exciting phase and supportthe company's mission to revolutionize neuromodulation therapy for overactive bladder."
  • "Dr. Kwo is a distinguished physician, leader, and entrepreneur with extensive knowledge in building and scaling healthcare products to improve outcomes and quality care," said Dan Lemaitre, Chairman and CEO of BlueWind Medical.
  • BlueWind Medical is an innovative medical device company that is transforming neuromodulation therapy for the treatment of Overactive Bladder (OAB).

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Sandoz Canada continues to expand its portfolio of generic products

Retrieved on: 
Wednesday, September 21, 2022

PrSandoz Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.

Key Points: 
  • PrSandoz Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.
  • BOUCHERVILLE, Quebec, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. is proud to announce the launch of several products that will expand its portfolio of high-quality generics.
  • Sandoz Canada is committed to its role in the healthcare sector and our teams are constantly working to expand our product portfolio to improve patient access to affordable, high-quality medicines.
  • Our products will generate substantial savings that can be reinvested for the benefit of Canadians, says Michel Robidoux, President and General Manager of Sandoz Canada.